Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2019

Open Access 01-12-2019 | Metastasis | Research

Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study

Authors: Pengfei Yu, Yian Du, Zhiyuan Xu, Ling Huang, Xiangdong Cheng

Published in: World Journal of Surgical Oncology | Issue 1/2019

Login to get access

Abstract

Background

The optimal extent of lymph node (LN) dissection for advanced distal gastric cancer remains controversial. The present study compared the safety and efficacy of extended LN dissection (D2 plus) with standard D2 radical surgery for advanced distal gastric cancer.

Methods

Eligible patients were enrolled and randomly assigned into two groups: D2 group and D2 plus group. Patients in the D2 group received standard D2 LN dissection, while patients in the D2 plus group received an additional nos. 8p, 12b, 13, and 14v LNs dissection. The clinicopathological and surgical data of these two groups were compared, and the factors that may influence survival were analyzed.

Results

Seventy patients were enrolled, out of which 64 patients were analyzed. There were no significant differences in the operative time, blood loss, and complications between the two groups. In the D2 plus group, the positive rate of the nos. 12b, 13, and 14v LN was 3.1%, 9.4%, and 12.5%, respectively. The positive rate of the no. 13 LN correlated with the duodenal involvement, while the positive rate of the no. 14v LN correlated with no. 6 LN metastasis. The survival analysis indicated that among patients with duodenum involvement, the 3-year disease-free survival rate of the D2 plus group was significantly better than that of the D2 group.

Conclusion

Duodenum involvement and positive no. 6 LN were high-risk factors of advanced distal gastric cancer. D2 plus radical surgery turned out to be safe and feasible, and may improve the prognosis of these patients. However, further clinical trials are still warranted.

Trial registration

This study is registered with ClinicalTrials.gov as NCT01836991, registered on 22 April 2013.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
2.
go back to reference Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial investigators: trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2012;376:687–97.CrossRef Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial investigators: trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2012;376:687–97.CrossRef
3.
go back to reference Chang SC, Liu KH, Hung CY, et al. Adjuvant chemotherapy improves survival in stage III gastric cancer after D2 surgery. J Cancer. 2018;9:81–91.CrossRef Chang SC, Liu KH, Hung CY, et al. Adjuvant chemotherapy improves survival in stage III gastric cancer after D2 surgery. J Cancer. 2018;9:81–91.CrossRef
4.
go back to reference Sasako M. Gastric cancer eastern experience. Surg Oncol Clin N Am. 2012;21:71–7.CrossRef Sasako M. Gastric cancer eastern experience. Surg Oncol Clin N Am. 2012;21:71–7.CrossRef
5.
go back to reference Wu L, Zhang C, Liang Y, et al. Risk factors for metastasis to no.14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery. Jpn J Clin Oncol. 2018;48:335–42.CrossRef Wu L, Zhang C, Liang Y, et al. Risk factors for metastasis to no.14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery. Jpn J Clin Oncol. 2018;48:335–42.CrossRef
6.
go back to reference Du Y, Cheng X, Xu Z, et al. D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction. Chin J Cancer Res. 2013;25:479–81.PubMedPubMedCentral Du Y, Cheng X, Xu Z, et al. D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction. Chin J Cancer Res. 2013;25:479–81.PubMedPubMedCentral
7.
go back to reference Tokunaga M, Ohyama S, Hiki N, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol. 2009;16:1241–6.CrossRef Tokunaga M, Ohyama S, Hiki N, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol. 2009;16:1241–6.CrossRef
8.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 4). Gastric Cancer. 2017;2014:1–19.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 4). Gastric Cancer. 2017;2014:1–19.CrossRef
9.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
10.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley-Blackwell; 2010. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley-Blackwell; 2010.
11.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef
12.
go back to reference Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305.CrossRef Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305.CrossRef
13.
go back to reference Mocellin S. The effect of lymph node dissection on the survival of patients with operable gastric carcinoma. JAMA Oncol. 2016;2:1363–4.CrossRef Mocellin S. The effect of lymph node dissection on the survival of patients with operable gastric carcinoma. JAMA Oncol. 2016;2:1363–4.CrossRef
14.
go back to reference Douridas GN, Pierrakakis SK. Is there any role for D3 lymphadenectomy in gastric cancer? Front Surg. 2018;5:27.CrossRef Douridas GN, Pierrakakis SK. Is there any role for D3 lymphadenectomy in gastric cancer? Front Surg. 2018;5:27.CrossRef
15.
go back to reference Bostanci EB, Kayaalp C, Ozogul Y, et al. Comparison of complications after D2 and D3 dissection for gastric cancer. Eur J Surg Oncol. 2004;30:20–5.CrossRef Bostanci EB, Kayaalp C, Ozogul Y, et al. Comparison of complications after D2 and D3 dissection for gastric cancer. Eur J Surg Oncol. 2004;30:20–5.CrossRef
16.
go back to reference Bostanci EB, Ozer I, Ercan M, et al. A prospective observational study of 468 patients undergoing D2 or D3 lymphadenectomy for gastric cancer. Hepato-Gastroenterology. 2013;60:624–7.PubMed Bostanci EB, Ozer I, Ercan M, et al. A prospective observational study of 468 patients undergoing D2 or D3 lymphadenectomy for gastric cancer. Hepato-Gastroenterology. 2013;60:624–7.PubMed
17.
go back to reference Zhang H, Liu C, Wu D, et al. Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference. BMC Cancer. 2010;10:308.CrossRef Zhang H, Liu C, Wu D, et al. Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference. BMC Cancer. 2010;10:308.CrossRef
18.
go back to reference Kumagai K, Sano T, Hiki N, et al. Survival benefit of “D2-plus” gastrectomy in gastric cancer patients with duodenal invasion. Gastric Cancer. 2018;21:296–302.CrossRef Kumagai K, Sano T, Hiki N, et al. Survival benefit of “D2-plus” gastrectomy in gastric cancer patients with duodenal invasion. Gastric Cancer. 2018;21:296–302.CrossRef
19.
go back to reference Eom BW, Joo J, Kim YW, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669–75.CrossRef Eom BW, Joo J, Kim YW, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669–75.CrossRef
20.
go back to reference Eom BW, Joo J, Kim YW, et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery. 2014;155:408–16.CrossRef Eom BW, Joo J, Kim YW, et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery. 2014;155:408–16.CrossRef
21.
go back to reference Liang H, Deng J. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. Chin J Cancer Res. 2016;28:397–403.CrossRef Liang H, Deng J. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. Chin J Cancer Res. 2016;28:397–403.CrossRef
22.
go back to reference Chen QY, Huang CM, Lin JX, et al. Laparoscopic infrapyloric area lymph node dissection with no. 14v enlargement for advanced lower gastric cancer in middle colic vein approach. Ann Surg Oncol. 2016;23:951.CrossRef Chen QY, Huang CM, Lin JX, et al. Laparoscopic infrapyloric area lymph node dissection with no. 14v enlargement for advanced lower gastric cancer in middle colic vein approach. Ann Surg Oncol. 2016;23:951.CrossRef
Metadata
Title
Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study
Authors
Pengfei Yu
Yian Du
Zhiyuan Xu
Ling Huang
Xiangdong Cheng
Publication date
01-12-2019
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2019
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-019-1572-1

Other articles of this Issue 1/2019

World Journal of Surgical Oncology 1/2019 Go to the issue